{"id":"comparator-niacin","safety":{"commonSideEffects":[{"rate":"75-90","effect":"Flushing"},{"rate":"20-30","effect":"Pruritus"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Hyperuricemia"},{"rate":"<1","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL573","moleculeType":"Small molecule","molecularWeight":"123.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Niacin acts as a lipid-modifying agent that decreases the synthesis and secretion of very low-density lipoprotein (VLDL) from the liver, thereby reducing circulating triglycerides and LDL cholesterol while simultaneously increasing HDL cholesterol levels. It also reduces free fatty acid mobilization from adipose tissue. These combined effects improve the lipid profile and may reduce cardiovascular risk.","oneSentence":"Niacin (vitamin B3) raises HDL cholesterol and lowers triglycerides and LDL cholesterol by inhibiting hepatic VLDL production and increasing apolipoprotein A-I.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:05.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia; elevated triglycerides and/or low HDL cholesterol"},{"name":"Cardiovascular risk reduction in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06582706","phase":"PHASE1, PHASE2","title":"Nicotinic Acid for the Treatment of Alzheimer's Disease","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-12-19","conditions":"Alzheimer Disease","enrollment":30},{"nctId":"NCT07245979","phase":"NA","title":"Supplementation With Sirtuin Activators in Women With Increased Body Weight","status":"RECRUITING","sponsor":"Poznan University of Life Sciences","startDate":"2025-10-08","conditions":"Obesity & Overweight","enrollment":120},{"nctId":"NCT03568968","phase":"PHASE3","title":"A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2020-05-06","conditions":"Parkinson Disease","enrollment":410},{"nctId":"NCT05452772","phase":"PHASE2","title":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-11-01","conditions":"Tobacco Use Disorder","enrollment":66},{"nctId":"NCT04573153","phase":"PHASE2, PHASE3","title":"Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients","status":"TERMINATED","sponsor":"ScandiBio Therapeutics AB","startDate":"2020-09-21","conditions":"COVID-19","enrollment":100},{"nctId":"NCT04078178","phase":"NA","title":"Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Steven E Arnold, MD","startDate":"2020-10-30","conditions":"Cognition Disorders in Old Age, Mild Cognitive Impairment, Cognitive Decline","enrollment":61},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT06382688","phase":"NA","title":"IV Administration of ChromaDex's Niagen® as Compared to NAD+","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nutraceuticals Research Institute","startDate":"2023-11-13","conditions":"Healthy Aging","enrollment":53},{"nctId":"NCT06189105","phase":"NA","title":"Efficacy and Safety Assessment of Niacinamide Cosmetic Preparation: a Randomized Controlled Trial","status":"UNKNOWN","sponsor":"University of Split, School of Medicine","startDate":"2023-06-03","conditions":"Skin Hyperpigmentation, Dry Skin; Eczema","enrollment":25},{"nctId":"NCT02109614","phase":"EARLY_PHASE1","title":"Early Aortic Valve Lipoprotein(a) Lowering Trial","status":"WITHDRAWN","sponsor":"George Thanassoulis","startDate":"2014-05","conditions":"Aortic Stenosis and Lipoprotein(a) Levels","enrollment":""},{"nctId":"NCT03061474","phase":"PHASE2","title":"Nicotinamide as an Early Alzheimer's Disease Treatment","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2017-07-12","conditions":"Alzheimer's Disease, Mild Cognitive Impairment","enrollment":46},{"nctId":"NCT06073730","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Kunming Medical University","startDate":"2023-11-01","conditions":"Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia","enrollment":154},{"nctId":"NCT02627963","phase":"PHASE3","title":"A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)","status":"COMPLETED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2016-05-24","conditions":"Carcinoma, Renal Cell","enrollment":350},{"nctId":"NCT04649203","phase":"PHASE3","title":"Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2020-11-25","conditions":"Diabetic Neuropathies","enrollment":216},{"nctId":"NCT04708340","phase":"PHASE1, PHASE2","title":"Tolerability and Efficacy of RJX in Patients With COVID-19","status":"UNKNOWN","sponsor":"Reven Pharmaceuticals, Inc.","startDate":"2021-03-25","conditions":"COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2","enrollment":237},{"nctId":"NCT04631536","phase":"PHASE3","title":"Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC","status":"UNKNOWN","sponsor":"Lebanese American University Medical Center","startDate":"2021-01-10","conditions":"Covid19","enrollment":42},{"nctId":"NCT05103709","phase":"NA","title":"Effect of Multiple Micronutrient Fortified Bread Consumption on Iron Deficiency Anemia in Women of Reproductive Age","status":"UNKNOWN","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2021-08-03","conditions":"Iron Deficiency Anemia","enrollment":351},{"nctId":"NCT01444807","phase":"PHASE2","title":"Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2011-12","conditions":"Metastatic Renal Cell Carcinoma","enrollment":132},{"nctId":"NCT01714609","phase":"PHASE2","title":"The Effect of Sorafenib on Portal Pressure","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-08","conditions":"Clinically Significant Portal Hypertension","enrollment":10},{"nctId":"NCT00769132","phase":"PHASE1","title":"A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08-03","conditions":"Hypercholesterolemia","enrollment":26},{"nctId":"NCT00479882","phase":"PHASE3","title":"MK-0524B Lipid Study (MK-0524B-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-15","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":2414},{"nctId":"NCT00872365","phase":"NA","title":"Effect of Micronutrients and Exercise During Pregnancy on Factors Related With Non-Transmissible Chronic Diseases","status":"COMPLETED","sponsor":"Universidad del Valle, Colombia","startDate":"2011-03","conditions":"Preeclampsia, Pregnancy, Micronutrients","enrollment":320},{"nctId":"NCT00533312","phase":"PHASE2","title":"MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-04","conditions":"Hypercholesterolemia","enrollment":407},{"nctId":"NCT00269217","phase":"PHASE3","title":"Lipid Efficacy Study (0524B-022)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":1400},{"nctId":"NCT00111891","phase":"PHASE2","title":"An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":"Dyslipidemia","enrollment":575},{"nctId":"NCT00533676","phase":"PHASE2","title":"Endpoint Validation Study (0524A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-08","conditions":"Flushing","enrollment":165},{"nctId":"NCT00533611","phase":"PHASE3","title":"Effect of MK0524A on Flushing Caused by Niacin (0524A-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Flushing","enrollment":330},{"nctId":"NCT00108485","phase":"PHASE3","title":"Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy","status":"TERMINATED","sponsor":"University of Miami","startDate":"2005-04","conditions":"Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia","enrollment":9},{"nctId":"NCT01012219","phase":"PHASE1","title":"A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Primary Hypercholesterolemia, Mixed Hyperlipidemia","enrollment":36},{"nctId":"NCT01071291","phase":"PHASE1","title":"Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02","conditions":"Dyslipidemia","enrollment":37},{"nctId":"NCT00485758","phase":"PHASE3","title":"Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Diabetes Mellitus Type 2","enrollment":796},{"nctId":"NCT00384293","phase":"PHASE3","title":"Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-09","conditions":"Hypercholesterolemia, Familial","enrollment":937},{"nctId":"NCT00618995","phase":"PHASE1","title":"A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-08","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT00536510","phase":"PHASE3","title":"Effect of MK0524A on Cholesterol Levels (0524A-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hypercholesterolemia, Hyperlipidemia","enrollment":646},{"nctId":"NCT00536237","phase":"PHASE2","title":"MK0524A Phase IIb Study (0524A-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-08","conditions":"Flushing","enrollment":154},{"nctId":"NCT01104519","phase":"PHASE1","title":"A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Dyslipidemia","enrollment":12},{"nctId":"NCT00944645","phase":"PHASE1","title":"MK0524A Bioequivalence Study (0524A-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10","conditions":"Dyslipidemia","enrollment":188},{"nctId":"NCT00479388","phase":"PHASE3","title":"Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":1216},{"nctId":"NCT00895193","phase":"NA","title":"Alternative Options to Minimize Niacin-Induced Flushing","status":"COMPLETED","sponsor":"Patrick Moriarty, MD, FACP, FACC","startDate":"2009-01","conditions":"Hypercholesterolemia, Flushing","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1635,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Niaspan"],"phase":"phase_3","status":"active","brandName":"Comparator: niacin","genericName":"Comparator: niacin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Niacin (vitamin B3) raises HDL cholesterol and lowers triglycerides and LDL cholesterol by inhibiting hepatic VLDL production and increasing apolipoprotein A-I. Used for Dyslipidemia; elevated triglycerides and/or low HDL cholesterol, Cardiovascular risk reduction in patients with established coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}